Predictive Oncology's Strategic Move with Reverse Stock Split

Author: Evelyn Baker Updated: 09-25-2025 10:43 AM

Predictive Oncology's Reverse Stock Split Overview

Predictive Oncology Inc. (NASDAQ: POAI), an innovator in AI-driven drug development, has recently announced a significant financial decision. The company will implement a 1-for-15 reverse stock split, effective shortly. This strategic move aims to align with Nasdaq's listing requirements, ensuring their continued presence in the capital market.

Details of the Reverse Stock Split

Effective at 12:01 a.m. on the specified date, Predictive Oncology's shares will undergo an automatic conversion. Each 15 shares of existing common stock will be combined into one new share. This is a pivotal moment for the company, which previously had around 11.4 million shares outstanding, and, after the consolidation, the total will reduce to approximately 762,414 shares, not including adjustments for rounding.

Why the Reverse Split Was Necessary

The main goal of this reverse stock split is to meet the minimum bid price required for maintaining the company's listing on the Nasdaq. The approval from shareholders reflects their alignment with this strategy, voted on in a recent special meeting. This move is crucial, as compliance with Nasdaq requirements directly influences Predictive Oncology's ability to operate in the market and attract future investments.

Impact on Shareholders

For shareholders, this reverse stock split will not change their percentage of ownership in the company. However, those holding fractional shares will see these shares rounded up to the nearest whole number. Predictive Oncology emphasizes that for stockholders with shares held through brokerage accounts, adjustments will be made automatically, ensuring a smooth transition.

Future of Predictive Oncology

Predictive Oncology continues to push the boundaries of cancer treatment through its AI platform, PEDAL. This platform is not only scientifically validated but is proving effective, predicting tumor responses with great accuracy. As the company moves forward, the integration of advanced technology into drug discovery will play a vital role in shaping future cancer therapies.

Contact Information for Inquiries

Shareholders or interested parties can reach out for more information or with any questions about the reverse stock split. The company encourages all stockholders to contact Pacific Stock Transfer, their transfer agent, for assistance. Also, Michael Moyer from LifeSci Advisors remains a key contact for investor relations.

Frequently Asked Questions

What is a reverse stock split?

A reverse stock split is a process where a company consolidates its shares to reduce the total number of shares outstanding, which can help boost the stock price.

Why did Predictive Oncology decide to undertake a reverse stock split?

The reverse stock split was necessary to meet Nasdaq's minimum bid price requirement, which is essential for maintaining their stock market listing.

How will this split affect my shares?

Your percentage ownership in the company remains the same. However, fractional shares will be rounded up to the next whole number.

Where can I get more information about the reverse stock split?

For specific inquiries, stockholders should reach out to Pacific Stock Transfer or Michael Moyer from LifeSci Advisors.

What does Predictive Oncology do?

Predictive Oncology uses its AI platform to accelerate drug discovery processes, aiming to improve treatment outcomes for cancer patients.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.